Category Archives: Industry

SEATTLE, Feb. 18, 2020 /PRNewswire/ — LumiThera Inc., a commercial stage medical device company delivering photobiomodulation (PBM) treatment for ocular disorders and diseases, today announced it has initiated further studies with the University of Wisconsin-Milwaukee to establish the use of their Photobiomodulation platform in Diabetic Retinopathy (DR).

“Recent research in our labs in both preclinical and clinical areas have indicated potential in treating diabetic edema with PBM,” stated Janis Eells, Ph.D., Professor, University of Wisconsin-Milwaukee. “Our work shows that early PBM benefits in reducing the detrimental effects of high glucose on retinal cells and early human data is now starting to show benefits in the clinical setting.”

DR is the leading cause of blindness in the world. The International Diabetes Foundation 2019 Fact Sheet estimated that globally 463 million people have diabetes now, and future estimates … Continue reading →

Dwight Heron, former director of oncology at UPMC International, co-founded REDjuvenate LLC, a company that uses photobiomodulation to treat skin problems, muscle aches and pains and other issues.

Dr. Heron, a noted radiation oncologist, said he is finishing his UPMC career with a six-month sabbatical. Dr. Heron’s center is the first in the region to use NovoTHOR equipment.

“After a few treatments, you begin seeing the effect,” Dr. Heron said about photobiomodulation therapy. “We think there’s some real opportunities here.”

Read the full article on Pittsburgh Post-Gazette

SEATTLE, Oct. 1, 2019 /PRNewswire/ — LumiThera Inc., a commercial stage medical device company delivering photobiomodulation (PBM) treatment for ocular disorders and disease, today announced it has begun enrolling patients in a multi-center United States clinical study in dry Age-Related Macular Degeneration (AMD) patients.

The randomized, multi-center study called LIGHTSITE III enrolled and treated the first patient at Cumberland Valley Retina in Hagerstown, Maryland. The United States study is being conducted in leading retinal centers throughout the United States. The study will enroll approximately 100 patients suffering from dry AMD and treat them over the course of two years. In addition to demonstrating safety, key efficacy endpoints include visual acuity, contrast sensitivity and reduction of drusen deposits.

In February, the company announced that the National Institute of Health and the division of the National Eye Institute was providing a $2.5M grant to partially support the U.S. study.

“This is an … Continue reading →